From Yahoo Finance: 2025-06-23 01:40:00

Lilly will acquire Verve Therapeutics, Inc. for up to $1.3 billion, offering $10.50 per share in cash plus a contingent value right of up to $3.00 per share. The deal is expected to close in Q3 2025, representing a 113% premium over Verve’s 30-day average share price.

Verve Therapeutics is developing single-dose gene-editing therapies for cardiovascular disease, including their flagship program VERVE-102 targeting PCSK9. The medication, in Phase 1b with FDA Fast Track designation, aims to transform care for patients with familial hypercholesterolemia and coronary artery disease.

Lilly sees Verve’s platform as strengthening their cardiometabolic pipeline. CEO Sekar Kathiresan emphasizes the shift from chronic to one-time care. Insiders owning 17.8% of Verve have agreed to tender their shares in the acquisition.

Verve’s potential as an investment is noted, but some believe AI stocks offer greater upside. For undervalued AI stocks with potential from Trump-era tariffs, see a free report on the best short-term AI stock.

No disclosures were made in the article.

Read more: Lilly To Acquire Verve For One-Time Cardiovascular Treatments